Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT06305754 |
Title | Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) |
Acronym | MK-2870-009 |
Recruitment | Recruiting |
Gender | both |
Phase | Phase III |
Variant Requirements | No |
Sponsors | Merck Sharp & Dohme LLC |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | USA | FRA | ESP |